Last reviewed · How we verify
NCT06172686
In-vivo Transmission Model in Semi-immune Adults
Phase 1 trial testing Piperaquine tablets , which will be administered orally as a single dose of 480mg (320mg+160mg). in Controlled Human Malaria Infection in 24 participants. Status unknown.
13 February 2024
Quick facts
| Lead sponsor | Ifakara Health Institute |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 24 |
| Start date | 9 January 2024 |
| Primary completion | 13 February 2024 |
| Estimated completion | 30 June 2024 |
| Sites | 1 location across Tanzania |
Drugs / interventions tested
- Piperaquine tablets , which will be administered orally as a single dose of 480mg (320mg+160mg). — full drug profile →
- Doxycycline (100mg tablets strength as Doxycycline Hyclate) will also be administered orally and will be given as 1 tablet (100mg) Once daily for 7 days.
Conditions studied
- Controlled Human Malaria Infection — all drugs for Controlled Human Malaria Infection →
- Induced Blood Stage Malaria Infection — all drugs for Induced Blood Stage Malaria Infection →
- Malaria Transmission — all drugs for Malaria Transmission →
- Malaria Challenge — all drugs for Malaria Challenge →
Sponsor
Ifakara Health Institute
Who can join
Adults 18 to 45, male only, with Controlled Human Malaria Infection or Induced Blood Stage Malaria Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Controlled human malaria infection (CHMI) has revolutionized the development of malaria vaccines. It involves the administration of either known numbers of sporozoites or infected erythrocytes to healthy human volunteers under a controlled environment. The use of highly sensitive molecular malaria diagnostic methods informs treatment decisions before symptom development and allows the characterization of parasite growth dynamics. Sporozoite CHMI has safely been used in six countries in Africa providing a platform to assess the efficacy of candidate malaria vaccines and study the natural immunity to malaria. Blood stage CHMI involves administration of known number of Artemether Lumefantrine sensitive infected erythrocytes in healthy volunteers, and it is a more sensitive model for modelling parasite growths and study the efficacy of blood-stage malaria vaccines. It has been safely used in Australia and Europe but not in Africa. Adaptation of this model by administration of combination of suboptimal and optimal antimalarial drugs lead to increased gametocytaemia, and infection rates in mosquitoes following standard membrane feeding assay. Such adaptation allows the model to be used to study parasite transmission from human to mosquitoes and evaluate transmission blocking malaria interventions. There is an urgent need to establish an in vivo model for early-stage clinical evaluation of transmission blocking interventions (TBI) in volunteers living in malaria endemic countries. This would allow rapid and cost-effective way to down-select transmission blocking candidate malaria vaccine and gametocidal antimalarial drugs before larger, more complex, and expensive field efficacy studies are conducted. A study done in naïve individual showed 100% success in establishing a malaria infection using 2800 P. falciparum infected RBCs, while a recent study (manuscript in development) has demonstrated success in establishing infection in Tanzanian semi-immune individuals with low malaria exposure using 1000 P. falciparum infected RBCs. We will use 1000 ALU-sensitive 3D7 P. falciparum infected RBCs to establish an in vivo transmission model for studying Transmission blocking interventions and assess the efficiency of two antimalarial drugs regimens (Piperaquine and doxycycline) to induce high levels of gametocytaemia and mosquito infection rates in healthy African adults. We will also investigate the determinants of successful transmission to mosquitoes including underlying immune responses to both asexual and sexual malaria antigens, asexual parasite dynamics and gametocyte burden, sex ratio of male and female gametocytes, and the relationship between gametocyte density and mosquito infection rate
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06172686
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Ifakara Health Institute trials
Trials by the same sponsor.
- NCT05125133 — Evaluation of Insecticide-treated Eave Nets and Window Screens for Malaria Control in Tanzania. · NA · unknown
- NCT04944966 — Safety and Efficacy of Maytenus Senegalensis for the Treatment of Uncomplicated Malaria · Phase 2 · completed
- NCT01930331 — Safety, Tolerability, Pharmacokinetics and Efficacy of ARCO · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06172686 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ifakara Health Institute
- Last refreshed: 15 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06172686.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing